TWi Pharma Granted US Orphan Drug Designation for Lead Molecule
October 21, 2014 at 10:28 AM EDT
TWi Pharma of Taiwan has been granted Orphan Drug designation in the US by the FDA for the use of AC-201 to treat a rare genetic skin disease, epidermolysis bullosa. EB, which affects one person out of every 50,000 births, results in extremely fragile skin that blisters and tears from friction or trauma. In June 2014, TWi established a China connection by acquiring a majority stake in Visum Pharma, located in Hainan. More details.... Share this with colleagues: // //